Skip to main content

Advertisement

SpringerLink
Log in

COX-2 inhibitors in rheumatoid arthritis

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

The selective cyclooxygenase 2 (COX-2) inhibitors have emerged as an important option in the treatment of rheumatoid arthritis (RA). Rofecoxib and celecoxib, the selective COX-2 inhibitors currently available, have shown efficacy in reducing symptoms of RA comparable with that of traditional nonsteroidal antiinflammatory drugs (NSAIDs). The primary advantage of selective COX-2 inhibitors relates to reduced gastrointestinal (GI) toxicity. Gastroduodenal ulcers detected by endoscopy are markedly diminished in patients receiving selective COX-2 inhibitors versus those receiving NSAIDs. Moreover, unpublished data indicate that the risk of symptomatic and complicated ulcers is reduced by approximately half in patients prescribed rofecoxib or celecoxib. Despite these encouraging findings, selective COX-2 inhibitors have the potential for important adverse events such as impaired renal function, hypertension, and edema. Furthermore, clinicians must balance the competing demands of reducing GI risk while managing the increasing costs associated with selective COX-2 inhibitor use.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Vane JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971, 231:232–235.

    PubMed  CAS  Google Scholar 

  2. Vane JR, Botting RM: Mechanism of action of nonsteroidal anti-inflammatory drugs. Am J Med 1998, 104:2S-8S.

    Article  PubMed  CAS  Google Scholar 

  3. Meade EA, Smith WL, DeWitt DL: Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1993, 268:6610–6614.

    PubMed  CAS  Google Scholar 

  4. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR: Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 1999, 96:7563–7568.

    Article  PubMed  CAS  Google Scholar 

  5. Harris RC, McKanna JA, Akai Y, Jacobson HR, Dubois RN and Breyer MD: Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest 1994, 94:2504–2510.

    PubMed  CAS  Google Scholar 

  6. Komhoff M, Grone HJ, Klein T, Seyberth HW, Nusing RM: Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: implication for renal function. Am J Physiol 1997, 272:F460-F468.

    PubMed  CAS  Google Scholar 

  7. Griffiths R: Prostaglandins and inflammation. In Inflammation: Basic Principles and Clinical Correlates, Edited by Gallin JI, Snydermans R. Philadelphia: Lippincott Williams & Wilkins; 1999:349–360.

    Google Scholar 

  8. Hishinuma T, Nakamura H, Sawai T, Uzuki M, Itabash Y, Mizugaki M: Microdetermination of prostaglandin E2 in joint fluid in rheumatoid arthritis patients using gas chromatography/selected ion monitoring. Prostaglandins Other Lipid Mediat 1999, 58:179–186.

    Article  PubMed  CAS  Google Scholar 

  9. Sano H, Hla T, Maier JA, Crofford LJ, Case JP, Maciag T, Wilder RL: In vivo cyclooxygenase expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis and rats with adjuvant and streptococcal cell wall arthritis. J Clin Invest 1992, 89:97–108.

    PubMed  CAS  Google Scholar 

  10. Crofford LJ, Wilder RL, Ristimaki AP, Sano H, Remmers EF, Epps HR, Hla T: Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. Effects of interleukin-1 beta, phorbol ester, and corticosteroids. J Clin Invest 1994, 93:1095–1101.

    Article  PubMed  CAS  Google Scholar 

  11. Seppala E, Nissila M, Isomaki H, Wuorela H, Vapaatalo H: Effects of non-steroidal anti-inflammatory drugs and prednisolone on synovial fluid white cells, prostaglandin E2, leukotriene B4 and cyclic AMP in patients with rheumatoid arthritis. Scand J Rheumatol 1990, 19:71–75.

    PubMed  CAS  Google Scholar 

  12. Fremont-Smith K, Bayles T: Salicylate therapy in rheumatoid arthritis. JAMA 1965, 192:1133.

    PubMed  CAS  Google Scholar 

  13. Borg AA, Fowler PD, Shadforth MF, Dawes PT: Use of the Stoke Index to differentiate between disease-modifying agents and non-steroidal anti-inflammatory drugs in rheumatoid arthritis. Clin Exp Rheumatol 1993, 11:469–472.

    PubMed  CAS  Google Scholar 

  14. Gotzsche PC: Meta-analysis of NSAIDs: contribution of drugs, doses, trial designs, and meta-analytic techniques. Scand J Rheumatol 1993, 22:255–260.

    PubMed  CAS  Google Scholar 

  15. Luggen ME, Gartside PS, Hess EV: Nonsteroidal antiinflammatory drugs in rheumatoid arthritis: duration of use as a measure of relative value. J Rheumatol 1989, 16:1565–1569.

    PubMed  CAS  Google Scholar 

  16. Pincus T, Marcum SB, Callahan LF, et al.: Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: I. Nonsteroidal antiinflammatory drugs. J Rheumatol 1992, 19:1874–1884.

    PubMed  CAS  Google Scholar 

  17. Rochon PA, Gurwitz JH, Simms RW, Fortin PR, Felson DT, Minaker KL, Chalmers TC: A study of manufacturer-supported trials of nonsteroidal anti-inflammatory drugs in the treatment of arthritis. Arch Intern Med 1994, 154:157–163.

    Article  PubMed  CAS  Google Scholar 

  18. Wijnands M, van Riel P, van ’t Hof M, Gribnau F, van de Putte L: Longterm treatment with nonsteroidal antiinflammatory drugs in rheumatoid arthritis: a prospective drug survival study. J Rheumatol 1991, 18:184–187.

    PubMed  CAS  Google Scholar 

  19. Dukes MN, Lunde I: The regulatory control of non-steroidal anti-inflammatory agents. Eur J Clin Pharmacol 1981, 19:3–10.

    Article  PubMed  CAS  Google Scholar 

  20. Pincus T, Callahan LF: Variability in individual responses of 532 patients with rheumatoid arthritis to first-line and second-line drugs. Agents Actions Suppl 1993, 44:67–75.

    PubMed  CAS  Google Scholar 

  21. Huskisson EC, Woolf DL, Balme HW, Scott J, Franklin S: Four new anti-inflammatory drugs: responses and variations. Br Med J 1976, 1:1048–1049.

    PubMed  CAS  Google Scholar 

  22. Simon LS, Weaver AL, Graham DY, et al.: Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA 1999, 282:1921–1928.

    Article  PubMed  CAS  Google Scholar 

  23. Emery P, Zeidler H, Kvien TK, et al.: Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet 1999, 354:2106–2111.

    Article  PubMed  CAS  Google Scholar 

  24. Schnitzer TJ, Truitt K, Fleischmann R, et al.: The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Phase II Rofecoxib Rheumatoid Arthritis Study Group. Clin Ther 1999, 21:1688–1702. 22-24. These trials represent the entire published data set that describes the efficacy of the selective COX-2 inhibitors in rheumatoid arthritis and present evidence that COX-2 inhibitors reduce the incidence of gastroduodenal ulcers detected by endoscopy.

    Article  PubMed  CAS  Google Scholar 

  25. Schoen RT and Vender RJ: Mechanisms of nonsteroidal anti-inflammatory drug-induced gastric damage. Am J Med 1989, 86:449–458.

    Article  PubMed  CAS  Google Scholar 

  26. Gabriel SE, Jaakkimainen RL, Bombardier C: The cost-effectiveness of misoprostol for nonsteroidal antiinflammatory drug-associated adverse gastrointestinal events. Arthritis Rheum 1993, 36:447–459.

    Article  PubMed  CAS  Google Scholar 

  27. Hochberg MC: Association of nonsteroidal antiinflammatory drugs with upper gastrointestinal disease: epidemiologic and economic considerations. J Rheumatol 1992, 19(Suppl:36):63–67.

    Google Scholar 

  28. Gabriel SE, Jaakkimainen L, Bombardier C: Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991, 115:787–796.

    PubMed  CAS  Google Scholar 

  29. Tamblyn R, Berkson L, Dauphinee WD, et al.: Unnecessary prescribing of NSAIDs and the management of NSAIDrelated gastropathy in medical practice. Ann Intern Med 1997, 127:429–438.

    PubMed  CAS  Google Scholar 

  30. Wolfe MM, Lichtenstein DR and Singh G: Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999, 340:1888–99. This is a comprehensive yet concise update on the pathogenesis, prevention and treatment of nonsteroidal antiinflammatory drug-induced gastrointestinal toxicity.

    Article  PubMed  CAS  Google Scholar 

  31. Singh G: Recent considerations in nonsteroidal antiinflammatory drug gastropathy. Am J Med 1998, 105:31S-38S.

    Article  PubMed  CAS  Google Scholar 

  32. Graham DY, Agrawal NM, Roth SH: Prevention of NSAIDinduced gastric ulcer with misoprostol: multicentre, doubleblind, placebo-controlled trial. Lancet 1988, 2:1277–1280.

    Article  PubMed  CAS  Google Scholar 

  33. Silverstein FE, Graham DY, Senior JR, Davies HW, Struthers BJ, Bittman RM, Geis GS: Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995, 123:241–249.

    PubMed  CAS  Google Scholar 

  34. Hawkey CJ, Karrasch JA, Szczepanski L, et al.: Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 1998, 338:727–734.

    Article  PubMed  CAS  Google Scholar 

  35. Yeomans ND, Tulassay Z, Juhasz L, et al.: A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 1998, 338:719–726.

    Article  PubMed  CAS  Google Scholar 

  36. Ehsanullah RS, Page MC, Tildesley G, Wood JR: Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: controlled trial of ranitidine. BMJ 1988, 297:1017–1021.

    Article  PubMed  CAS  Google Scholar 

  37. Robinson MG, Griffin JW Jr., et al.: Effect of ranitidine on gastroduodenal mucosal damage induced by nonsteroidal antiinflammatory drugs. Dig Dis Sci 1989, 34:424–428.

    Article  PubMed  CAS  Google Scholar 

  38. Taha AS, Hudson N, Hawkey CJ, et al.: Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med 1996, 334:1435–439.

    Article  PubMed  CAS  Google Scholar 

  39. Agrawal NM, Roth S, Graham DY, White RH, Germain B, Brown JA, Stromatt SC: Misoprostol compared with sucralfate in the prevention of nonsteroidal anti-inflammatory drug-induced gastric ulcer. A randomized, controlled trial. Ann Intern Med 1991, 115:195–200.

    PubMed  CAS  Google Scholar 

  40. Hawkey C, Laine L, Simon T, et al.: Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebocontrolled trial. The Rofecoxib Osteoarthritis Endoscopy Multinational Study Group. Arthritis Rheum 2000, 43:370–377. This study describes the reduction in endoscopically detected gastroduodenal ulcers in patients taking rofecoxib.

    Article  PubMed  CAS  Google Scholar 

  41. Langman MJ, Jensen DM, Watson DJ, et al.: Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999, 282:1929–1933. This study presents the first evidence that patients receiving cyclooxygenase-2 inhibitors have fewer clinically important gastroduodenal ulcers than those receiving traditional nonsteroidal antiinflammatory drugs.

    Article  PubMed  CAS  Google Scholar 

  42. Cryer B, Feldman M: Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology 1999, 117:17–25.

    Article  PubMed  CAS  Google Scholar 

  43. Whelton A: Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med 1999, 106:13S-24S.

    Article  PubMed  CAS  Google Scholar 

  44. Rossat J, Maillard M, Nussberger J, Brunner HR, Burnier M: Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther 1999, 66:76–84.

    Article  PubMed  CAS  Google Scholar 

  45. Swan SK, Rudy DW, Lasseter KC, et al.: Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. Ann Intern Med 2000, 133:1–9.

    PubMed  CAS  Google Scholar 

  46. Perazella MA, Eras J: Are selective COX-2 inhibitors nephrotoxic? Am J Kidney Dis 2000, 35:937–940.

    PubMed  CAS  Google Scholar 

  47. Schafer AI: Effects of nonsteroidal anti-inflammatory therapy on platelets. Am J Med 1999, 106:25S-36S.

    Article  PubMed  CAS  Google Scholar 

  48. Leese PT, Hubbard RC, Karim A, Isakson PC, Yu SS, Geis GS: Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial. J Clin Pharmacol 2000, 40:124–132.

    Article  PubMed  CAS  Google Scholar 

  49. Karim A, Tolbert DS, Hunt TL, Hubbard RC, Harper KM, Geis GS: Celecoxib, a specific COX-2 inhibitor, has no significant effect on methotrexate pharmacokinetics in patients with rheumatoid arthritis. J Rheumatol 1999, 26:2539–2543.

    PubMed  CAS  Google Scholar 

  50. Guidelines for monitoring drug therapy in rheumatoid arthritis. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Arthritis Rheum 1996, 39:723–731.

    Article  Google Scholar 

  51. Patterson R, Bello AE and Lefkowith J: Immunologic tolerability profile of celecoxib. Clin Ther 1999, 21:2065–2079.

    Article  PubMed  CAS  Google Scholar 

  52. Wolfe F, Zhao S and Lane N: Preference for nonsteroidal antiinflammatory drugs over acetaminophen by rheumatic disease patients: a survey of 1,799 patients with osteoarthritis, rheumatoid arthritis, and fibromyalgia. Arthritis Rheum 2000, 43:378–385.

    Article  PubMed  CAS  Google Scholar 

  53. Guidelines for the management of rheumatoid arthritis. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Arthritis Rheum 1996, 39:713–722.

    Article  Google Scholar 

  54. Peterson WL, Cryer B: COX-1-sparing NSAIDs--is the enthusiasm justified?. JAMA 1999, 282:1961–1963. This editorial provides a thoughtful approach to the competing concerns of minimizing nonsteroidal antiinflammatory druginduced gastrointestinal toxicity while managing the impact of medication costs.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Duke Clinical Research Institute, 2400 Pratt Street, Room 0311, Terrace Level, 27705, Durham, NC, USA

    John S. Sundy MD, PhD

Authors
  1. John S. Sundy MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sundy, J.S. COX-2 inhibitors in rheumatoid arthritis. Curr Rheumatol Rep 3, 86–91 (2001). https://doi.org/10.1007/s11926-001-0055-9

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-001-0055-9

Keywords

Search

Navigation